Alkyl Amines

    ALKYLAMINE
    Chemicals·6 Nov 2025
    Management Summary

    Alkyl Amines reported a subdued first half of FY26 with flat topline and marginally higher volumes, primarily due to demand pressures and geopolitical actions by the US government impacting exports and increasing Chinese competition. Despite these challenges, the company managed to retain profitability and stable gross margins. Management is optimistic about a new import-substitute product commercializing in Q1 FY26-27 and expects better performance from Acetonitrile in the coming quarters, while acknowledging an overhang in methylamine capacity.

    Highlights5
    • Marginal volume growth achieved despite subdued demand pressures.
    • Profitability and gross margins were retained and protected.
    • New import-substitute product (₹120 crores CAPEX) expected to be profitable with superior technology, commercializing Q1 FY26-27.
    • Acetonitrile market is growing with new uses, and anti-dumping duties are expected to yield better results from Q4 FY26.
    • Ethylamine capacity utilization is at 60-70% with significant headroom for growth.
    Concerns Noted5
    • Subdued demand pressures led to a flat topline for the first half of FY26.
    • FY26 volume growth is expected to be subdued, falling short of the normal 10-15% target.
    • US government actions (sanctions, tariffs) negatively impacted direct exports, customer demand, and intensified Chinese competition.
    • Full benefits of anti-dumping duties on Acetonitrile are not yet realized due to aggressive Chinese price dropping.
    • Methylamine market faces significant capacity overhang with a new player (Aarti Drugs) entering the market.
    What Changed1

    vs Q4 FY26

    Guidance items4 → 6 (+2)
    Capital1

    Capital Allocation

    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Promises6

    Guidance & Targets

    CategoryTargetPriority
    Volume
    FY26 Volume GrowthSubdued (not normal 10-15%)
    High
    Volume
    Total Volumes (Run Rate)Cross 100,000 tons
    High
    New Product
    New Product CommercializationQ1 FY26-27
    High
    Acetonitrile
    Acetonitrile Volume & Price ImprovementReal benefit coming in, mainly volume
    High
    Regulatory
    Isopropylamine Duty Protection DecisionExpect something
    High
    R&D
    R&D Pipeline Investment DecisionsMake some decisions
    High
    Watchlist5

    Watch for Next Quarter

    #Metric
    01FY26 Volume Growth
    02Acetonitrile Volume & Price Improvement
    03Isopropylamine Duty Protection Decision
    04R&D Pipeline Investment Decisions
    05Raw Material Price Stability
    Risks5

    Risks & Concerns

    SeverityRisk
    high

    Subdued demand pressures

    Volumes marginally up, topline flat, and FY26 growth expected to be subdued due to overall market conditions.

    Management
    high

    Impact of US government actions (sanctions, tariffs)

    Affected direct exports to the US, customer demand, and led to aggressive Chinese competition in the domestic market.

    Management
    medium

    Chinese dumping in ex-US markets

    Chinese players are pushing material to Asia, affecting domestic prices and limiting the benefits of anti-dumping duties.

    Management
    medium

    Methylamine capacity overhang

    Entry of a new player (Aarti Drugs) has added to existing overcapacity in the methylamine market.

    Management
    medium

    Raw material price volatility (ammonia) due to Middle East disruptions

    US sanctions on Iran are impacting the supply chain, with a short-term price blip expected, though normalization is anticipated in the long run.

    Management
    Q&A8

    Q&A Highlights

    Narrative2m

    Detailed Narrative

    6 chapters
    01

    Subdued Performance in H1 FY26 Amidst Geopolitical Headwinds

    Alkyl Amines experienced a subdued first half of FY26, with volumes marginally up but topline remaining flat due to subdued prices. The company successfully managed its margins to retain profitability. This performance was primarily attributed to demand pressures and the multi-faceted impact of US government actions, including affected direct exports, reduced customer demand, and increased aggressive competition from Chinese players in the domestic market.

    02

    Methylamine and Ethylamine Market Dynamics

    The impact of subdued demand was more pronounced on methylamines compared to ethylamines, which are largely domestically focused. While ethylamine prices have gone down, leading to an impact on contribution per kg, overall contribution and gross margins remained stable. The methylamine market faces an overhang in capacity, with a total market size of 80,000-90,000 tons for four players against a capacity exceeding 1,50,000 tons, exacerbated by Aarti Drugs commissioning a new plant.

    03

    Strategic Product Development and Capacity Expansion

    The company is progressing with a new import-substitute product at Kurkumbh, with mechanical completion expected by February-March 2026 and commercialization in Q1 FY26-27. This project involves a capital expenditure of approximately ₹120 crores and is anticipated to be a profitable product with superior technology, targeting dyes, pigments, and electronics sectors. The company's total production capacity is estimated at up to 2 lakh tons, with a saleable capacity of about 1.5 lakh tons after accounting for internal consumption.

    04

    Acetonitrile Market Challenges and Opportunities

    The acetonitrile market, while growing with new uses, has not yet fully benefited from anti-dumping duties imposed at the end of June. Although prices have marginally improved, aggressive price dropping by Chinese competitors has limited the full impact of the duties. Management expects to see real benefits, primarily in volume, from Q4 FY26 onwards. The company is also exporting acetonitrile worldwide and is considered the number one Indian player.

    05

    Raw Material Supply Chain and Pricing Outlook

    Recent Middle East disruptions and US sanctions on Iran have impacted the supply chain for raw materials like ammonia, which are sourced through distributors. While the company's current material requirements are covered, a short-term blip in prices is anticipated. However, management expects the supply chain to readjust quickly due to alternate routes and market flexibility, leading to price normalization in the long run, as there is an overall capacity overhang for these products globally.

    06

    Future Growth and R&D Pipeline

    Alkyl Amines maintains an active R&D pipeline with a couple of new products under consideration for future investments. Decisions regarding these investments, which will be in areas of the company's technological strengths, are expected within the next 3 to 6 months. The company aims to return to its normal growth trajectory as global trade situations stabilize, having already surpassed 2019 volumes and profitability levels.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.